Faculty profile
Jean-Pierre Ayoub
Back to facultyResearch
Read how they describe their research on their Université de Montréal profile.
Latest papers
Efficacy and safety of first-line veliparib and carboplatin–paclitaxel in patients with HER2− advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial
European Journal of Cancer · 2021
Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience.
The oncologist · 2021
Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial.
Therapeutic advances in medical oncology · 2021 · first author
7 publications.
Efficacy and safety of first-line veliparib and carboplatin–paclitaxel in patients with HER2− advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial
Banu Arun, Hyo Sook Han, Bella Kaufman, Hans P. M. W. Wildiers, Michael Leonard Friedlander, Jean-Pierre Ayoub, Shannon L. Puhalla, Katherine M. Bell‐McGuinn, Bruce Allen Bach, Madan G. Kundu, Christine K. Ratajczak, David Maag, Veronique C Dieras
Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience.
Jolivet C, Nassabein R, Soulières D, Weng X, Amireault C, Ayoub JP, Beauregard P, Blais N, Carrier C, Cloutier AS, Desnoyers A, Lemay AS, Lemay F, Loungnarath R, Jolivet J, Letendre F, Tehfé M, Vadnais C, Viens D, Aubin F
Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial.
Ayoub JP, Wildiers H, Friedlander M, Arun BK, Han HS, Puhalla S, Shparyk Y, Jakobsen EH, Wu M, Bach BA, Feng D, Ratajczak CK, Maag D, Diéras V
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
Veronique C Dieras, Hyo Sook Han, Bella Kaufman, Hans P. M. W. Wildiers, Michael Leonard Friedlander, Jean-Pierre Ayoub, Shannon L. Puhalla, Igor Bondarenko, Mario Campone, Erik Jakobsen, Mathilde Jalving, Cristina Marinela Oprean, Markéta Palácová, Yeon Hee Park, Yaroslav V. Shparyk, Eduardo Yáñez, Nikhil Khandelwal, Madan G. Kundu, Matthew W. Dudley, Christine K. Ratajczak, David Maag, Banu Arun
Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy
Bradbury PA, Morris DG, Nicholas G, Tu D, Tehfe M, Goffin JR, Shepherd FA, Gregg RW, Rothenstein J, Lee C
Early investigation by fluor-18-fluorodeoxyglucose positron emission tomography of a metastatic basal cell carcinoma presenting with spinal cord compression: A case report.
Arsenault F, Ayoub JP, Danilenko A, Boucher L
Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
Hirsh V, Soulieres D, Duclos M, Faria S, Del Vecchio P, Ofiara L, Ayoub JP, Charpentier D, Gruber J, Portelance L, Souhami L
Frequent collaborators
- Lesley Seymour and Dongsheng Tu: 55 shared papers
- John Goffin and Dongsheng Tu: 29 shared papers
- John Goffin and Lesley Seymour: 20 shared papers
- Lesley Seymour and Normand Blais: 5 shared papers
- John Goffin and Natasha Leighl: 4 shared papers
- John Goffin and Normand Blais: 4 shared papers
- Lesley Seymour and Natasha Leighl: 4 shared papers
- Dongsheng Tu and Harriet Feilotter: 4 shared papers
- Dongsheng Tu and Normand Blais: 4 shared papers
- Danielle Charpentier and Francine Aubin: 4 shared papers
- John Goffin and Harriet Feilotter: 3 shared papers
- John Goffin and Francine Aubin: 3 shared papers
- Dongsheng Tu and Natasha Leighl: 3 shared papers
- Dongsheng Tu and Francine Aubin: 3 shared papers
- Lesley Seymour and Harriet Feilotter: 2 shared papers
- Michael Friedlander and Jean-Pierre Ayoub: 2 shared papers
- Normand Blais and Jean-Pierre Ayoub: 2 shared papers
- Danielle Charpentier and Denis Soulières: 2 shared papers
- John Goffin and Jean-Pierre Ayoub: 1 shared paper
- Lesley Seymour and Jean-Pierre Ayoub: 1 shared paper
- Dongsheng Tu and Jean-Pierre Ayoub: 1 shared paper
- Harriet Feilotter and Denis Soulières: 1 shared paper
- Harriet Feilotter and Jean-Pierre Ayoub: 1 shared paper
- Natasha Leighl and Jean-Pierre Ayoub: 1 shared paper
- Normand Blais and Denis Soulières: 1 shared paper
- Danielle Charpentier and Jean-Pierre Ayoub: 1 shared paper
- Denis Soulières and Jean-Pierre Ayoub: 1 shared paper
- Luc Boucher and Jean-Pierre Ayoub: 1 shared paper
- Francine Aubin and Jean-Pierre Ayoub: 1 shared paper
- Department of Medicine
- Department of Oncology
- Department of Mathematics
- Department of Mathematics and Statistics
- Pathology
- Department of Radiology, Radiation Oncology and Nuclear Medicine
Co-authors at Université de Montréal, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Michael Friedlander
Department of Mathematics
2 shared papers, latest 2021
Normand Blais
Department of Medicine
2 shared papers, latest 2021
Lesley Seymour
Department of Oncology
1 shared papers, latest 2018
Dongsheng Tu
Department of Mathematics and Statistics
1 shared papers, latest 2018
Harriet Feilotter
Pathology
1 shared papers, latest 2018
Natasha Leighl
Department of Medicine
1 shared papers, latest 2018
Danielle Charpentier
Department of Medicine
1 shared papers, latest 2007
Denis Soulières
Department of Medicine
1 shared papers, latest 2007
Luc Boucher
Department of Radiology, Radiation Oncology and Nuclear Medicine
1 shared papers, latest 2015
John Goffin
Department of Oncology
1 shared papers, latest 2018
Francine Aubin
Department of Medicine
1 shared papers, latest 2021
Donald Morris
Oncology
1 shared papers, latest 2018
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.
Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.